TCR Repertoire Analysis During Therapeutic Interventions in Liver Diseases Using Next‐Generation Sequencing
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.16835 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Natsuko Nakakuki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Receptors, Antigen, T-Cell, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background and Aim The T cell receptor (TCR) can recognize a vast number of antigens and is closely associated with the pathogenesis of various diseases including autoimmune diseases and malignancies. However, the clinical significance of the TCR repertoire and its post‐treatment changes remain unclear in liver diseases.
Methods
We performed next‐generation sequencing (NGS)‐based TCR analysis using DNA obtained from peripheral blood mononuclear cells (PBMCs) of healthy donors (HD, n = 5), primary biliary cholangitis (PBC, n = 5), autoimmune hepatitis (AIH, n = 5), and hepatocellular carcinoma (HCC, n = 5) and evaluated the changes after treatment.
Results
Baseline TCR repertoire analysis demonstrated that TCR clonotype usage is restricted and diversity is low in all three disease groups (PBC, AIH, and HCC), particularly in PBC and AIH compared to HD ( p < 0.05). Following treatment, clonotype usage and diversity did not change significantly, except in AIH, where diversity decreased further ( p < 0.05 for clone Shannon diversity and clone evenness). Disease‐specific usage of TCR beta genes and specific changes after therapy were observed in all groups. Analysis of clonotypes shared with other individuals (public clonotypes) revealed that nine public clonotypes in PBC, eight in AIH, and eight in HCC disappeared after treatment. Motif analysis identified one characteristic motif (NQPQH) in PBC.
Conclusions
The diversity of the TCR repertoire, TCR beta chain usage, clonotypes, and motifs and their post‐treatment changes are disease‐specific in each liver disease, indicating that further TCR repertoire studies are needed to accelerate the understanding of liver disease pathogenesis from an immunological perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
ORCID-Profile: Shinya Maekawa, Shinichi Takano
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Nakakuki, N., Maekawa, S., Takano, S., Osawa, L., Komiyama, Y., Takada, H., Muraoka, M., Suzuki, Y., Sato, M., & Enomoto, N. (2025). TCR Repertoire Analysis During Therapeutic Interventions in Liver Diseases Using Next‐Generation Sequencing. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16835
Vancouver
Nakakuki N, Maekawa S, Takano S, Osawa L, Komiyama Y, Takada H, et al. TCR Repertoire Analysis During Therapeutic Interventions in Liver Diseases Using Next‐Generation Sequencing. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16835
BibTeX
@article{Nakakuki2025,
author = {Nakakuki, Natsuko and Maekawa, Shinya and Takano, Shinichi and Osawa, Leona and Komiyama, Yasuyuki and Takada, Hitomi and Muraoka, Masaru and Suzuki, Yuichiro and Sato, Mitsuaki and Enomoto, Nobuyuki},
title = {TCR Repertoire Analysis During Therapeutic Interventions in Liver Diseases Using Next‐Generation Sequencing},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.16835}
}
EUVIMED